Stock screenerAll disclosures →
EDGAR →
INAB
Conviction 0HealthcareScan · Thu, Jun 25, 2026INAB$1.37-7.76%
ResistanceSupportVol 14Vol MA14 33.98K
Mar 26Apr 14May 1May 19Jun 8Jun 25
Price1.37
Change-7.76%
Gap-5.40%
Rel volume0.29×
Avg volume50.33K
Avg $ vol78.79K
SMA 201.50
SMA 501.53
SMA 2001.81
Price vs 50-10.80%
Price vs 200-24.60%
MA stackbearish
50/200 cross—
Supertrenddown · 1.65
RSI (14)39
MACD hist-0.00
MACD cross—
Stoch %K / %D18 / 46
ADX (14)14
+DI / −DI19 / 26
RSI divergence—
MACD divergence—
ATR %+6.87%
ADR %6.01%
52w high2.59
52w low1.21
From 52w high-47.30%
Above 52w low+12.81%
New 52w highNo
SqueezeOff
Bollinger width36.04%
%B0.24
Donchian pos7.71%
Donchian high1.88
Donchian low1.32
AVWAP (52w high)1.72
vs AVWAP high-20.59%
AVWAP (52w low)1.55
vs AVWAP low-12.08%
OBV trendDown
Chaikin MF (20)-0.04
Today vs 20d0.29×
Avg vol (14d)33.98K
Avg vol (20d)50.33K
Avg $ vol (20d)78.79K
Market cap13.44M
RS 3m (vs SPY)-16.78%
RS 6m (vs SPY)+14.57%
RS line new highNo
Trend template0/8
Technical rank14.3
1 week-7.14%
1 month-19.23%
3 months-15.22%
6 months-11.94%
1 year-39.06%
YTD-44.51%
P/E-0.69
P/B0.59
P/S—
P/FCF—
EPS-4.44
Div yield—
ROE-85.33%
ROA-74.01%
Debt/Eq—
Current10.50
EV/EBITDA—
Gross margin—
Net margin—
Rev growth—
EPS growth36.13%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value-8.72M
Revenue—
Net income-5.09M
Gross profit—
Free cash flow—
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out9.85M
Employees18
ListedFri, Jul 30, 2021
Free float6.96M
Float %70.7%
Short interest107.42K
Days to cover1.3d
Short volume37.5%
Squeeze score10 / 100
Next earningsThu, Aug 6, 2026 (42d)
EPS forecast−$0.61 · 1 est
Last EPS vs est—
Last surprise—
Setup gradeD
Conviction0 / 100
Pattern quality—
Tech rank14.3 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance1.82
Support1.35
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in INAB
No recent disclosed trades by Congress in INAB. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in INAB · 8 buys · 1 sell
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
FAIRBAIRN EMILY Director · Common Stock · 2026-05-27 | Gift | 724.64K | $0 | 2026-05-27 | 2026-05-29 |
FAIRBAIRN EMILY Director · Common Stock · 2026-05-27 | Other | — | — | 2026-05-27 | 2026-05-29 |
Ho William Tai-Wei CEO · Employee Stock Option (right to buy) · 2026-05-09 | Grant | 154.5K | $0 | 2026-05-09 | 2026-05-12 |
FAIRBAIRN EMILY Director · Stock Option (right to buy) · 2026-05-09 | Grant | 22K | $0 | 2026-05-09 | 2026-05-12 |
Epperly Corinne Director · Stock Option (right to buy) · 2026-05-09 | Grant | 22K | $0 | 2026-05-09 | 2026-05-12 |
Rochlin Kate President and COO · Employee Stock Option (right to buy) · 2026-05-09 | Grant | 60K | $0 | 2026-05-09 | 2026-05-12 |
Lamb Lawrence EVP and CSO · Employee Stock Option (right to buy) · 2026-05-09 | Grant | 54K | $0 | 2026-05-09 | 2026-05-12 |
Graff Jeremy R. Director · Stock Option (right to buy) · 2026-05-09 | Grant | 22K | $0 | 2026-05-09 | 2026-05-12 |
McCall Patrick CHIEF FINANCIAL OFFICER · Employee Stock Option (right to buy) · 2026-05-09 | Grant | 56.25K | $0 | 2026-05-09 | 2026-05-12 |
Greenwood Luba Director · Stock Option (right to buy) · 2026-05-09 | Grant | 22K | $0 | 2026-05-09 | 2026-05-12 |
SEC filings
EDGAR filings in INAB · 2 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.